Roundup: US FDA clears Medical IP’s AI body comp analysis software and more briefs

Medical IP gets US FDA nod for AI body composition analysis software

South Korean medical imaging company Medical IP has obtained a United States Food and Drug Administration 510(k) clearance for its AI-powered body composition analysis software. 

According to the company, DeepCatch is the first FDA-approved AI software that automatically analyses body components, such as skin, bone, muscle, visceral fat, subcutaneous fat, internal organ, and central nervous system, through whole-body CT. It provides reports with 3D visual and quantitative information. 

With this FDA clearance, Medical IP will be accelerating its plan to expand globally. 

Augnito launches ambient tech for clinical documentation

Indian health tech company Augnito has introduced ambient technology for clinical documentation.

Based on a press release, the technology enables doctors to document patient encounters and generate documentation and data. It transcribes the consultation between the doctor and patient in real-time with “absolute” accuracy, and then it generates a structured SOAP note.

It can transcribe other types of conversations, including chief complaints, medical history, diagnoses, recommended plans of care, prescriptions and details of a follow-up appointment, among others. Augnito’s AI can comprehend all English accents with 99% accuracy and transcribe multi-lingual conversations in over 10 Indian languages and Arabic. It also caters to over 50 medical specialties. 

The technology can also automate administrative tasks, such as charting, data input, and report generation, which doctors still have to do despite using an EMR system. 

Lunit-powered CXR solution eligible for reimbursement in Japan

Fujifilm’s AI solution for chest x-ray analysis, CXR-AID, which is powered by the Lunit INSIGHT CXR, has become eligible for health insurance reimbursement in Japan, Lunit announced. 

It is provided under the Ministry of Health, Labor, and Welfare’s reimbursement class 3 category for hospitals utilising AI image diagnostic software. CXR-AID is also one of the 17 recommended medical AI software options in the new Japan Radiological Society guideline for implementing AI solutions in hospitals. 

Based on a press release, the reimbursement inclusion “significantly boosts” the expansion of both Lunit and Fujifilm in the Japanese market, as well as creates new growth prospects in the field of AI image diagnostics.